uracil has been researched along with Innate Inflammatory Response in 23 studies
2,4-dihydroxypyrimidine: a urinary biomarker for bipolar disorder
| Excerpt | Relevance | Reference |
|---|---|---|
| "The results indicate that alogliptin improves stress-induced prothrombotic state and insulin resistance; suggesting that alogliptin could have beneficial therapeutic effects against cardiovascular complications in diabetic patients under stress." | 7.83 | Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model. ( Cheng, XW; Hao, CN; Hayashi, M; Kikuchi, R; Matsushita, T; Murohara, T; Nakamura, S; Nakayama, T; Takeshita, K; Uchida, Y; Wu, H; Yamamoto, K; Yisireyili, M, 2016) |
| "Hypochlorous acid (HOCl), generated from H2O2 and Cl- by myeloperoxidase in activated neutrophils, causes tissue damage during inflammation." | 7.72 | 5-Chlorouracil, a marker of DNA damage from hypochlorous acid during inflammation. A gas chromatography-mass spectrometry assay. ( Ames, BN; Blount, BC; Jiang, Q, 2003) |
| "Hydrogen-rich water has a significant protective effect on OGD/R-causing HT22 cell injury, and the mechanism may be related to the inhibition of autophagy." | 4.40 | Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19. ( , 2023) |
| "The results indicate that alogliptin improves stress-induced prothrombotic state and insulin resistance; suggesting that alogliptin could have beneficial therapeutic effects against cardiovascular complications in diabetic patients under stress." | 3.83 | Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model. ( Cheng, XW; Hao, CN; Hayashi, M; Kikuchi, R; Matsushita, T; Murohara, T; Nakamura, S; Nakayama, T; Takeshita, K; Uchida, Y; Wu, H; Yamamoto, K; Yisireyili, M, 2016) |
| " Here, we show that bacterial-derived uracil acts as a ligand for dual oxidase (DUOX)-dependent reactive oxygen species generation in Drosophila gut and that the uracil production in bacteria causes inflammation in the gut." | 3.79 | Bacterial-derived uracil as a modulator of mucosal immunity and gut-microbe homeostasis in Drosophila. ( Ha, EM; Kim, B; Kim, EK; Kim, MJ; Kim, SH; Kwon, Y; Lee, KA; Lee, WJ; Ryu, JH; You, H, 2013) |
| "Hypochlorous acid (HOCl), generated from H2O2 and Cl- by myeloperoxidase in activated neutrophils, causes tissue damage during inflammation." | 3.72 | 5-Chlorouracil, a marker of DNA damage from hypochlorous acid during inflammation. A gas chromatography-mass spectrometry assay. ( Ames, BN; Blount, BC; Jiang, Q, 2003) |
| "Alogliptin (Alo) is a dipeptidyl peptidase 4 (DPP-IV) inhibitor, which is booming as an antidiabetic agent." | 1.72 | Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade. ( Abdelhakeem, JI; ElGamal, MA; Nasr, MM; Roshdy, OK; Salama, RM, 2022) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (21.74) | 18.7374 |
| 1990's | 1 (4.35) | 18.2507 |
| 2000's | 4 (17.39) | 29.6817 |
| 2010's | 9 (39.13) | 24.3611 |
| 2020's | 4 (17.39) | 2.80 |
| Authors | Studies |
|---|---|
| Saunders, MJ | 1 |
| Edwards, BS | 1 |
| Zhu, J | 1 |
| Sklar, LA | 1 |
| Graves, SW | 1 |
| Harrison, SA | 1 |
| Bashir, MR | 1 |
| Guy, CD | 1 |
| Zhou, R | 1 |
| Moylan, CA | 1 |
| Frias, JP | 1 |
| Alkhouri, N | 1 |
| Bansal, MB | 1 |
| Baum, S | 1 |
| Neuschwander-Tetri, BA | 1 |
| Taub, R | 1 |
| Moussa, SE | 1 |
| Salama, RM | 1 |
| Nasr, MM | 1 |
| Abdelhakeem, JI | 1 |
| Roshdy, OK | 1 |
| ElGamal, MA | 1 |
| Meng, J | 1 |
| Zhang, W | 1 |
| Wang, C | 1 |
| Xiong, S | 1 |
| Wang, Q | 1 |
| Li, H | 1 |
| Liu, G | 1 |
| Hao, Z | 1 |
| Zhou, J | 1 |
| Peng, Z | 1 |
| Wang, J | 1 |
| Chestnova, TV | 1 |
| Zilov, VG | 1 |
| Gladkikh, PG | 1 |
| Khadartsev, AA | 1 |
| Korotkova, AS | 1 |
| Buzulukov, YP | 1 |
| Suzuki, M | 1 |
| Takaishi, S | 1 |
| Nagasaki, M | 1 |
| Onozawa, Y | 1 |
| Iino, I | 1 |
| Maeda, H | 1 |
| Komai, T | 1 |
| Oda, T | 1 |
| Lee, KA | 1 |
| Kim, SH | 1 |
| Kim, EK | 1 |
| Ha, EM | 1 |
| You, H | 1 |
| Kim, B | 1 |
| Kim, MJ | 1 |
| Kwon, Y | 1 |
| Ryu, JH | 1 |
| Lee, WJ | 1 |
| Yisireyili, M | 1 |
| Takeshita, K | 1 |
| Hayashi, M | 1 |
| Wu, H | 1 |
| Uchida, Y | 1 |
| Yamamoto, K | 1 |
| Kikuchi, R | 1 |
| Hao, CN | 1 |
| Nakayama, T | 1 |
| Cheng, XW | 1 |
| Matsushita, T | 1 |
| Nakamura, S | 1 |
| Murohara, T | 1 |
| Calkins, MJ | 1 |
| Vartanian, V | 1 |
| Owen, N | 1 |
| Kirkali, G | 1 |
| Jaruga, P | 1 |
| Dizdaroglu, M | 1 |
| McCullough, AK | 1 |
| Lloyd, RS | 1 |
| Kido, M | 1 |
| Takeuchi, S | 1 |
| Esaki, H | 1 |
| Hayashida, S | 1 |
| Furue, M | 1 |
| Shah, Z | 1 |
| Kampfrath, T | 1 |
| Deiuliis, JA | 1 |
| Zhong, J | 1 |
| Pineda, C | 1 |
| Ying, Z | 1 |
| Xu, X | 1 |
| Lu, B | 1 |
| Moffatt-Bruce, S | 1 |
| Durairaj, R | 1 |
| Sun, Q | 1 |
| Mihai, G | 1 |
| Maiseyeu, A | 1 |
| Rajagopalan, S | 1 |
| Ismagilova, AF | 1 |
| Gafiatullin, RR | 1 |
| Andriianov, VM | 1 |
| Ismagilov, FR | 1 |
| Henderson, JP | 2 |
| Byun, J | 2 |
| Takeshita, J | 1 |
| Heinecke, JW | 2 |
| Jiang, Q | 1 |
| Blount, BC | 1 |
| Ames, BN | 1 |
| Bogdanova, ASh | 1 |
| Bilich, GL | 1 |
| Nazarova, LV | 1 |
| Sungurova, EV | 1 |
| Williams, MV | 1 |
| Mueller, DM | 1 |
| McCormick, ML | 1 |
| Kagawa, M | 1 |
| Yamamoto, A | 1 |
| Ogawa, K | 1 |
| Shirai, T | 1 |
| Fukushima, S | 1 |
| Kamaev, MF | 1 |
| Rusakov, VI | 1 |
| Simet, L | 1 |
| Reisner, DB | 1 |
| Ludwig, BJ | 1 |
| Dürsch, F | 1 |
| Berger, FM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Mapping Organ Health Following COVID-19 Disease Due to SARS-CoV-2 Infection[NCT04369807] | 693 participants (Actual) | Observational | 2020-04-21 | Completed | |||
| A Phase 2, Multi-Center, Double-Blind, Randomized, Placebo-controlled Study of MGL-3196 in Patients With Non-alcoholic Steatohepatitis[NCT02912260] | Phase 2 | 125 participants (Actual) | Interventional | 2016-09-30 | Active, not recruiting | ||
| A Phase 1, Double-blind, Randomized, Placebo-controlled, First-in-human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Food-effect of Single and Multiple Oral Doses of RJ4287 in Healthy Volunteers[NCT05921006] | Phase 1 | 98 participants (Anticipated) | Interventional | 2023-06-13 | Recruiting | ||
| Improvement of Laboratory Diagnostics in Hypothyroid Patients Using Levothyroxine[NCT06083636] | 500 participants (Anticipated) | Observational | 2022-07-26 | Recruiting | |||
| Effects of Vildagliptin/Metformin Combination on Markers of Atherosclerosis, Thrombosis, and Inflammation in Diabetic Patients With Coronary Artery Disease[NCT01604213] | Phase 4 | 60 participants (Actual) | Interventional | 2012-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for uracil and Innate Inflammatory Response
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
[Antitrypsin activity of pentoxyl and dimethyl sulphoxide].
Topics: Adrenal Glands; Analgesics; Animals; Anti-Inflammatory Agents; Burns; Dimethyl Sulfoxide; Humans; In | 1972 |
2 trials available for uracil and Innate Inflammatory Response
| Article | Year |
|---|---|
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosp | 2023 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Topics: Adult; Alanine Transaminase; Biomarkers; Diarrhea; Double-Blind Method; Female; Humans; Inflammation | 2019 |
20 other studies available for uracil and Innate Inflammatory Response
| Article | Year |
|---|---|
Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
Topics: Animals; Biotinylation; Flow Cytometry; Fluorescence Resonance Energy Transfer; Green Fluorescent Pr | 2010 |
Alogliptin attenuates cyclophosphamide-induced nephrotoxicity: a novel therapeutic approach through modulating MAP3K/JNK/SMAD3 signaling cascade.
Topics: Animals; Cyclophosphamide; Inflammation; Male; Oxidative Stress; Piperidines; Rats; Rats, Wistar; Si | 2022 |
The dipeptidyl peptidase (DPP)-4 inhibitor trelagliptin inhibits IL-1β-induced endothelial inflammation and monocytes attachment.
Topics: Anti-Inflammatory Agents; Cell Adhesion; Cell Adhesion Molecules; Coculture Techniques; Cytokines; D | 2020 |
Trelagliptin Alleviates Lipopolysaccharide (LPS)-Induced Inflammation and Oxidative Stress in Acute Lung Injury Mice.
Topics: Acute Lung Injury; Animals; Inflammation; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Oxid | 2021 |
Combined Effect of Silver Nanoparticles, Ceftriaxone, and Methyluracil during Experimental Purulent Peritonitis.
Topics: Animals; Anti-Bacterial Agents; Biofilms; Ceftriaxone; Infectious Disease Medicine; Inflammation; Ma | 2018 |
Medium-chain fatty acid-sensing receptor, GPR84, is a proinflammatory receptor.
Topics: Animals; Cattle; Chemokine CXCL1; CHO Cells; Cricetinae; Cricetulus; Fatty Acids; Female; HEK293 Cel | 2013 |
Bacterial-derived uracil as a modulator of mucosal immunity and gut-microbe homeostasis in Drosophila.
Topics: Animals; Drosophila; Gastrointestinal Tract; Homeostasis; Humans; Immunity, Mucosal; Inflammation; I | 2013 |
Dipeptidyl peptidase- IV inhibitor alogliptin improves stress-induced insulin resistance and prothrombotic state in a murine model.
Topics: Adipose Tissue; Animals; Dipeptidyl Peptidase 4; Dipeptidyl-Peptidase IV Inhibitors; Disease Models, | 2016 |
Enhanced sensitivity of Neil1
Topics: Animals; Cytokines; DNA Damage; DNA Glycosylases; DNA Repair; Gene Expression Profiling; Gene Expres | 2016 |
Scratching behavior does not necessarily correlate with epidermal nerve fiber sprouting or inflammatory cell infiltration.
Topics: Animals; Anti-Inflammatory Agents; Disease Models, Animal; Epidermis; Female; Haptens; Inflammation; | 2010 |
Long-term dipeptidyl-peptidase 4 inhibition reduces atherosclerosis and inflammation via effects on monocyte recruitment and chemotaxis.
Topics: Animals; Apolipoproteins E; Atherosclerosis; Blood Pressure; Cell Movement; Chemotaxis; Dipeptidyl-P | 2011 |
[Studies of biological activity of mineral oil dialkyl disulfide (an experimental study)].
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents, Non-Steroidal; Burns; Central Nervous Sys | 2002 |
Phagocytes produce 5-chlorouracil and 5-bromouracil, two mutagenic products of myeloperoxidase, in human inflammatory tissue.
Topics: Bromouracil; Gas Chromatography-Mass Spectrometry; HL-60 Cells; Humans; Hydrogen-Ion Concentration; | 2003 |
5-Chlorouracil, a marker of DNA damage from hypochlorous acid during inflammation. A gas chromatography-mass spectrometry assay.
Topics: Alkaline Phosphatase; Animals; Biomarkers; Carrageenan; Cell Line; Chlorine; DNA; DNA Damage; Dose-R | 2003 |
[Influence of prodigiozan, methyluracil and levamisole on the anti-inflammatory effect of nonsteroid antiphlogistics].
Topics: Adjuvants, Immunologic; Animals; Anti-Inflammatory Agents; Carrageenan; Cyclophosphamide; Drug Evalu | 1984 |
The enzymatic status of circulating lymphocytes as an index of the regenerative process in the lungs under stimulation with pyrimidine and purine derivatives. A clinical experimental study.
Topics: Acid Phosphatase; Alkaline Phosphatase; Animals; Glycerolphosphate Dehydrogenase; Humans; Hypertroph | 1982 |
Production of brominating intermediates by myeloperoxidase. A transhalogenation pathway for generating mutagenic nucleobases during inflammation.
Topics: Bromine; Bromouracil; Deoxycytidine; DNA Damage; Humans; Hydrogen Peroxide; Hypochlorous Acid; Infla | 2001 |
Uracil-induced urolithiasis in the urinary bladder of rats is irritation-dependent.
Topics: Animals; Body Weight; Hydrogen-Ion Concentration; Inflammation; Male; Organ Size; Osmolar Concentrat | 1992 |
[Basis for the use of methyluracil and pentoxyl in surgery].
Topics: Humans; Inflammation; Surgical Procedures, Operative; Uracil; Wound Healing | 1971 |
Potential antiinflammatory agents. Aralkoxyhydrouracils and aralkoxyhydantoins.
Topics: Animals; Anti-Inflammatory Agents; Chemical Phenomena; Chemistry; Hydantoins; Inflammation; Kaolin; | 1970 |